IP Library Granted Patent US 10,036,054
Granted Patent B2
US 10,036,054 · App. 15/432,157 · Granted Jul 31, 2018

Bead beating tube and method for extracting deoxyribonucleic acid and/or ribonucleic acid from microorganisms

Inventors: Holger Klapproth (Freiburg, DE); Nicolaas Smit (Welland, CA)
Assignee: Safeguard Biosystems Holdings Ltd.
C12Q1/6806B01L3/5082C12M47/06C12Q1/6874B01L2300/16G01N2035/00524
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,036,054
App. No.
15/432,157
Granted
Jul 31, 2018
Kind
B2
Abstract

The present disclosure provides improved methods for bead beating and a bead beating system useful therefor. The bead beating system comprises a sample tube, beads, and a dry blocking agent, and methods for using the bead beating system to extract nucleic acids from cells containing the nucleic acids.

Claims (23)

1. A method for producing a lysate from cells contained in a liquid sample comprising blood or a sample processed, extracted or fractionated from blood, the method comprising:

(a) agitating the liquid sample within a bead beating system in the absence of lysis buffer and in the presence of one or more blocking agents under conditions sufficient to lyse the cells, said bead beating system comprising a bead beating tube and beads; and

(b) separating the liquid sample from the beads directly following the agitating,

thereby producing a lysate.

2. A method for producing a lysate from cells contained in a liquid sample comprising blood, the method comprising:

(a) agitating the liquid sample within a bead beating system in the absence of lysis buffer and in the presence of one or more blocking agents under conditions sufficient to lyse the cells, said bead beating system comprising a bead beating tube and beads; and

(b) separating the liquid sample from the beads following the agitating,

thereby producing a lysate.

3. The method of claim 2 , wherein the liquid sample contains an endogenous blocking agent.

4. The method of claim 3 , wherein the agitating is carried out in the absence of additives.

5. The method of claim 3 , wherein the agitating is carried out in the absence of additives which comprise a buffer.

6. The method of any one of claims 2 to 5 , wherein the agitating is carried out in the absence of additives which comprise a detergent.

7. The method of claim 1 or claim 2 , wherein the one or more blocking agents are exogenous to the liquid sample.

8. The method of claim 1 or claim 2 , further comprising a step of placing the liquid sample within the bead beating tube prior to agitating the liquid sample.

9. The method of claim 1 or claim 2 , wherein the agitating comprises subjecting the bead beating system to an oscillating motion.

10. The method of claim 1 or claim 2 , wherein the cells comprise one or more pathogens.

11. The method of claim 10 , wherein the one or more pathogens comprise one or more bacterial pathogens, viral pathogens, fungal pathogens, or a combination thereof.

12. The method of claim 10 , wherein the one or more pathogens comprise one or more of Mycobacterium tuberculosis, Mycobacterium avium subsp paratuberculosis, Staphylococcus aureus , methicillin resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, Haemophilus influenzae, Haemophilus parainfuluezae, Moraxella catarrhalis, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter sp., Bordetella pertussis, Neisseria meningitidis, Bacillus anthracis, Nocardia sp., Actinomyces sp., Mycoplasma pneumoniae, Chlamydia pneumonia, Legionella species, Pneumocystis jiroveci , influenza A virus, cytomegalovirus, rhinovirus, Enterococcus faecium, Acinetobacter baumannii, Corynebacterium amycolatum, Enterobacter aerogenes, Enterococcus faecalis CI 4413, Serratia marcescens, Streptococcus equi , and Candida albicans.

13. The method of claim 1 , wherein the liquid sample comprises blood.

14. The method of claim 1 , wherein the liquid sample comprises a sample processed, extracted or fractionated from blood.

15. The method of claim 1 or claim 2 , wherein step (b) comprises pipetting the liquid sample from the bead beating tube, thereby leaving behind the beads in the bead beating tube.

16. The method of claim 1 or claim 2 , further comprising purifying the nucleic acids from the lysate.

17. The method of claim 16 , further comprising analyzing one or more of the nucleic acids.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2024
From: IP SUCCESSOR FUND 21 L.P.
To: SAFEGUARD BIOSYSTEMS HOLDINGS LIMITED
Reel/Frame 069084/0644 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2024
From: MLC50 LP INC.
To: SAFEGUARD BIOSYSTEMS HOLDINGS LIMITED
Reel/Frame 069084/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2024
From: SAFEGUARD BIOSYSTEMS HOLDING LIMITED
To: SAFEGUARD DX LIMITED
Reel/Frame 069088/0245 →
SECURITY INTEREST Recorded Aug 16, 2024
From: SAFEGUARD BIOSYSTEMS HOLDINGS LIMITED
To: MLC50 LP INC.
Reel/Frame 068317/0453 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SAFEGUARD BIOSYSTEMS HOLDINGS LIMITED
To: IP SUCCESSOR FUND 21 L.P.
Reel/Frame 055411/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2017
From: KLAPPROTH, HOLGER; SMIT, NICOLAAS
To: SAFEGUARD BIOSYSTEMS HOLDINGS LTD.
Reel/Frame 041251/0957 →
Priority Claims (1)
EP 16153540 · Jan 30, 2016 · regional
Continuity (2)
Continuation PCTEP2017051902 · Jan 30, 2017
Related Publication 20170218356A1 · Aug 3, 2017